DUBLIN--(BUSINESS WIRE)--Sep 14, 2018--The "Allergic Rhinitis - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

Allergic Rhinitis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Allergic Rhinitis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Allergic Rhinitis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Allergic Rhinitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 7, 13, 3, 1, 11, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 2 and 4 molecules, respectively.

Allergic Rhinitis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered

Introduction Allergic Rhinitis - Overview Allergic Rhinitis - Therapeutics Development Allergic Rhinitis - Therapeutics Assessment Allergic Rhinitis - Companies Involved in Therapeutics Development Allergic Rhinitis - Drug Profiles Allergic Rhinitis - Dormant Projects Allergic Rhinitis - Discontinued Products Allergic Rhinitis - Product Development Milestones

Companies Featured

Accolade Pharmaceuticals LLC AFFiRiS AG ALK-Abello AS AlleCures Inc AOBiome LLC ASIT Biotech SA Chong Kun Dang Pharmaceutical Corp Chrysalis BioTherapeutics Inc CSPC Pharmaceutical Group Limited Daewon Pharm Co Ltd Fountain Biopharma Inc GlaxoSmithKline Plc Glenmark Pharmaceuticals Ltd HAL Allergy BV Hanlim Pharm Co Ltd iCo Therapeutics Inc Inimmune Corp Intrommune Therapeutics Laboratorios LETI SL Marinomed Biotech AG Mitsubishi Tanabe Pharma Corp Paradigm Biopharmaceuticals Ltd Pfizer Inc Regeneron Pharmaceuticals Inc Stallergenes Greer plc The Geneva Biotech Center SA Xencor Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/bsn93f/allergic_rhinitis?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180914005394/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Allergy Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/14/2018 11:45 AM/DISC: 09/14/2018 11:45 AM